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Abstract Major scientific advances in basic science, phar-
macology, and translational medicine have allowed the dis-
covery of new molecular targets whose manipulation by new
chemical entities has led to treatments for inflammatory dis-
eases, including rheumatoid arthritis, multiple sclerosis, and
inflammatory bowel disease. Development of new agents for
systemic lupus erythematosus (SLE) has lagged, however,
because the protean manifestations of SLE present challenges
for measuring therapeutic effects in a consistent manner.
Composite end points combining several Disease Activity
Indices (DAIs) are being used in ongoing global studies, but
the uniform application of these complex DAIs across large
numbers of clinical sites has proven difficult. We describe
herein approaches that are being utilized to facilitate collec-
tion, review, and analysis of the clinical measures utilizing
independent central adjudication committees.
Keywords Systemiclupuserythematosus .SLE .Data
quality .Challenge .Newagents .Therapy .Central
adjudicationcommittees .DiseaseActivityIndex .Trials .
Optimize
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease with a wide array of clinical and laboratory mani-
festations that can affect every body system [1–3]. The
pathogenesis of SLE involves genetic, immunologic, hor-
monal, and environmental factors, and current therapies
include NSAIDs, antimalarials, corticosteroids, and immu-
nosuppressive agents. Despite the use of non–target-specif-
ic, steroid-sparing, immunosuppressive agents such as
methotrexate, azathioprine, mycophenolate mofetil, and cy-
clophosphamide, most patients require the ongoing use of
low- to mid-dose levels of corticosteroids together with
intermittent bursts of high doses [3–5]. The morbidity of
these treatments prevents many of these patients from living
productive lives, particularly those who are diagnosed in
their early reproductive years. Patients with moderate to
severe, remitting, relapsing disease would be better served
by agents that target more specific immunologic molecular
targets. The basic science, pharmacology, and translational
medicine efforts for the discovery of therapies to alter new
molecular targets have advanced significantly over the past
25 years; however, the protean nature of SLE has made it
challenging to develop reproducible and scalable measures
of disease activity that are applicable to global clinical trials
requiring 150 to 300 investigative sites. Drug development
for SLE has therefore lagged behind that of other inflam-
matory autoimmune diseases such as rheumatoid arthritis,
multiple sclerosis, and inflammatory bowel disease [8–11].
Several Disease Activity Indices (DAIs) have been and
are currently being used for the development of composite
primary end points to test a number of therapeutics that are
in clinical development for moderate to severe SLE. These
DAIs include versions of the SLE Disease Activity Index
(SLEDAI), including the original SLEDAI, which is
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ward the neurological and renal systems that are deemed
“present or not present” within the previous 10 days of the
assessment [12, 13]. The clinical parameters are given
weighted scores of 1 to 8. The Safety of Estrogens in Lupus
Erythematosus, National Assessment–Systemic Lupus
Erythematosus Disease Activity Index (SELENA-SLEDAI),
extended the original SLEDAI to include a flare index to
measure moderate and severe flares over time in an SLE
population whose disease was minimally active at baseline
[14, 15]. The SLEDAI-2000, a modification of the original 24
SLEDAI clinical parameters, was developed to take into ac-
count persistent disease activity rather than only new or recur-
rent features of SLE [16]. It has been shown to be valid over
both 30-day and 10-day periods [17].
Another commonly utilized DAI for SLE activity is the
BILAG (British Isles Lupus Assessment Group) Index
[18–20]. The BILAG is a group of physicians who have
been meeting regularly since 1984, and originally produced
what has become known as the “classic” BILAG Index,
which consists of 86 clinical and laboratory parameters
measured over a 28-day period. It is based upon a physi-
cian’s intention to treat and captures changes in active
disease in different body systems simultaneously. The body
systems included in the original version included constitu-
tional, mucocutaneous, neuropsychiatric, musculoskeletal,
cardiovascular, vasculitis, renal, and hematological. The
classic BILAG underwent a major revision in 2004 to re-
move some damage items, increase the number of parame-
ters to 97, add the gastrointestinal (GI) and ophthalmic
systems, and include vasculitis terms within the appropriate
body systems [21]. These parameters are scored by the
treating physician as new (4), worse (3), same (2), improv-
ing (1), and not present (0). Within the nine body systems,
grades of A through E are assigned based on a severity
scoring index. While it is a complex instrument to use, it
has been validated and shown to correlate with a physician’s
intent to treat [22].
The SELENA-SLEDAI modification of the Physician’s
GlobalAssessment,orMDGA,isathree-inchvisualanalogue
scale(VAS)withsuperimposedlandmarksrangingfrom0to3
inwhichzeroisequivalentto nodisease activity,and 1,2,and
3 correlate with mild, moderate, and the most severe disease
possible, respectively. Note that an MDGA of 2.5 will trigger
a severe flare by SELENA-SLEDAI criteria [14, 15]. Some
studies have used a VAS of 100 mm, similar to that used in
rheumatoid arthritis studies [23, 24￿￿], which can also be
successfully used in lupus trials with the SELENA-SLEDAI
landmarks. The use of this instrument in clinical trials is
dependent upon having sequential determinations performed
by the same physician, as it is largely subjective.
In contrast to these activity indices, the Systemic Lupus
International Collaborating Clinics/ACR (SLICC/ACR) is a
measure of damage or nonreversible change present for at
least 6 months that is not related to ongoing active inflam-
mation [25, 26].
The first drug to be approved for SLE in 60 years was
belimumab, a monoclonal antibody that inhibits the activity
of the B-lymphocyte stimulator (BLyS) [27, 28]. This drug
was approved by the US Food and Drug Administration
(FDA) in March 2011 [29]. The primary end point used in
the two registration trials was the Systemic Lupus Response
Index (SRI) [30￿￿, 31￿￿, 32￿￿]. The SRI is a composite index
composed of a ≥4-point decrease in the SLEDAI, the ab-
sence of new flares in any of the eight body systems defined
by no new A scores (representing severe disease activity),
and no more than one new B score (representing moderate
disease activity) in the classic BILAG, and no worsening
(≥0.3 increase) of the MDGA visual analogue three-point
score [30￿￿]. Using this composite end point, there was a
modest but statistically significant increase in the response
rate in patients receiving 10 mg/kg belimumab for 52 weeks
[31￿￿, 32￿￿]. In the two trials that had identical entry criteria,
BLISS-52 and BLISS-76 showed placebo response rates of
34 % or 44 %, and belimumab (10 mg/kg) response rates of
43 % and 58 % [31￿￿, 32￿￿]. This represented treatment
effects of only 9 % and 14 %, respectively; however, all
secondary end points demonstrated directional improvement
in the treatment groups, the most important of which was a
higher percentage of patients whose average prednisone
dose was reduced by 25 % or more from baseline to
≤7.5 mg/d during weeks 40 through 52 [31￿￿, 32￿￿]. The
main driver of the SRI was the 4-point or greater reduction
in the SLEDAI score., Placebo rates of 34 % and 44 % may
have been high because of the remitting and relapsing nature
of the disease and because the patients were allowed
increases in standard-of-care medications during the first
part of the study, many of which can be quite effective.
Another targeted therapy currently in phase 3 is epratu-
zumab, which is a monoclonal antibody directed against the
CD22 antigen on the B-cell surface [33–35]. Using the same
DAIs, a different composite primary end point was indepen-
dently developed and used in the EMBLEM phase 2 study
[33]. The primary end point was the BILAG Based Com-
posite Lupus Assessment (BICLA) at 12 weeks composed
of BILAG 2004 improvement, defined as BILAG A’sa t
study entry improved to B/C/D and BILAG B’s at study
entry improved to C/D and no BILAG worsening in other
BILAG organ systems, no worsening in SLEDAI total score
compared with study entry, no worsening in physician’sg l o b -
al VAS assessment of disease activity (defined as <10 %
increase) compared with study entry; moreover, patients
who are treatment failures cannot be responders [33, 36￿￿].
The results of the EMBLEM study showed that 21 % of
patients receiving placebo met all criteria defined in the
BICLA. Patients treated with epratuzumab in a total dose of
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4 3%a t1 2w e e k s[ 33]. Although the treatment groups
contained a relatively small number of patients (37–39 per
arm), the lower placebo response resulted in the realization of
a statistically significant, approximately twofold treatment
effect.
The EMBLEM data were subjected to post-hoc anal-
ysis comparing the BICLA versus SRI composite end
points [37￿￿]. Application of the SRI to these data
showed a placebo efficacy rate of greater than 50 %,
or twice that observed when data were analyzed by
BICLA criteria. No treatment effect was observed using
SRI [37￿￿]. Improvement using the BILAG-based BICLA
requires a response in all body systems that were involved at
baseline, as well as no new flares in the remaining body
systems, which may account for the fact that a placebo re-
sponse occurs less often. By contrast, if just one SLEDAI
element worth at least four points resolves, while other fea-
tures that were present at baseline stay the same or worsen
slightly, then the patient could qualify as a responder in the
SRI.
A similar analysis was applied to preliminary data
obtained in the Biomarkers of Lupus Disease (BOLD) study,
a study of 100 patients with SLE on immunosuppressive
therapy [38￿￿]. Half of the patients are undergoing with-
drawal of their immunosuppressive therapy to determine
whether this would be safe and lessen the time to flare.
The placebo effect was examined using multiple outcome
measures including the SRI-4, SRI-5, and a stringent end
point similar to the BICLA, which did not, however, allow a
responder to have even one B flare. These end points were
compared with BOLD study protocol criteria minimally
defined by either a ≥drop of one BILAG grade or a SLEDAI
≥4-point reduction from baseline but anchored by the inves-
tigators’simple intent-to-treat–based determination, whether
there was clinically significant improvement, no significant
change, or clinically significant flare. A preliminary analysis
at 4 and 8 weeks showed that the BICLA-like end point was
superior to SRI in detecting improvement, and less likely to
pick up a flare visit as improvement based on the BOLD
standard [38￿￿].
The potential for variability in the application of the
SLEDAI, BILAG, and MDGA by physician evaluators
worldwide poses a large challenge in multicenter clinical
trials given the differences in disease expression in individ-
ual patients and the interpretation of the patient signs and
symptoms. The focus of this article is on analyzing the
potential pitfalls in the collection of clinical trial data in
patients with SLE, describing approaches that have been
used in the successful development of drugs for other clin-
ical indications, and presenting solutions for assuring the
uniformity of the data across multiple SLE clinical trial
sites.
Centralized Adjudication Committees for Complex
Clinical End Points
Centralized adjudication committees (CACs) have been
used successfully to analyze clinical end points that are not
solely composed of objective laboratory data and are thus
subject to variable and/or biased interpretation. These adju-
dication committees are different from data monitoring com-
mittees (also known as data safety monitoring committees or
DMCs), which are a group of individuals established for
large, randomized, multicenter trials in which a treatment is
intended to reduce mortality or major cardiovascular events,
recurrence of cancer, or other life-threatening events [39].
These committees are used in trials predominantly to mon-
itor study treatments or procedures in which the results
could possibly have a very favorable or highly unfavorable
impact on safety, or in trials in which particularly fragile
populations are involved and in whom the risk of mortality
or other serious outcomes is high [39]. A DMC may be
charged with determining whether trials should be aborted
for futility if efficacy is found to be absent or if a detrimental
effect on the population is discovered. Conversely, a trial
may be stopped if the treatment is shown in an interim
analysis to have a very favorable outcome such that it would
be unethical to continue withholding therapy in a placebo-
controlled trial.
IncontrasttoDMCs,CACsprovidemoredetailed,specific
data review, predominantly of efficacy end points [40, 41].
Given the investment of hundreds of millions of dollars re-
quired to bring a drug to late-stage development, and the
intense level of audit and scrutiny applied to trial data before
marketing approval of drugs and devices, most companies
have employed centralized review and adjudication to assure
bias-free interpretation of critical end points.
CACs are routinely used to analyze cardiac and pulmo-
nary events for safety and efficacy [42, 43]. Criteria are
developed prospectively for determining classification of
events into myocardial infarction, acute coronary syndrome
without infarction, appropriate application of angioplasty
and stenting procedures, episodes of congestive heart failure,
and respiratory deaths due to various causes [44, 45]. Studies
have shown that there can be substantial discrepancies be-
tween evaluation of these events by the site investigator as
compared with the central committee [43–45]. A recent anal-
ysis of clinical event classification (CHF and cardiogenic
shock) for the Assessment of Pexelizumab in Acute Myocar-
dial Infarction (APEX-AMI) trial showed that the clinical
events committee agreed with site investigator assessments
of CHF in only 45 % of CHF events, and 77 % of cardiogenic
shock events [44].
In the Understanding the Potential Long-term Impacts on
Function with Tiotropium (UPLIFT) trial, conducted in
patients with chronic obstructive pulmonary disease
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cause-specific mortality due to respiratory, cancer, cardio-
vascular, sudden cardiac death, or sudden death, which was
then compared with the site investigator assessment. In this
study, there was complete agreement in only 50.2 %, in-
complete agreement in 18.5 %, and no agreement in 31 % of
981 reported deaths. Thus, there is a high degree of vari-
ability in relying upon individual site assessments in classi-
fying causes of what is usually considered a “hard” end
point, mortality [45].
Assessments of complete and partial responses and time
to progression in oncology trials are particularly difficult.
These determinations are dependent upon physical exami-
nation and radiological imaging techniques, which are in-
herently variable. Central adjudication of these end points is
critical for oncology drug development and provisional
marketing approval in the absence of long-term mortality
data [46, 47].
Disease Activity Index Interpretation in Systemic Lupus
Erythematosus Clinical Trials
The FDA guidance for the development of drugs for lupus
specifies that sponsors should use an adjudication commit-
tee to determine whether patients meet prespecified criteria
for responder status [48￿￿]. The following describes two
general approaches that can be utilized.
Post-Hoc Versus Ongoing Data Review and Adjudication
in Systemic Lupus Erythematosus Trials
Adjudication can be performed when all patient visits are
finalized and after site personnel have applied the DAIs to
serial patient visits and assigned scores to BILAG, SLEDAI,
and MDGA. The cumulative data are then provided to
members of a CAC who have developed specific rules for
verifying the correct application of the DAIs. All visits for a
patient are reviewed and queries are issued to investigators
to clarify the interpretation and correct application of the
disease measurement tools. The advantage of this approach
is that the adjudicator can assess the patient over the entire
period of time being studied in sequential visits, which can
help detect potentially illogical patterns in the data, but the
disadvantage is that a significant amount of time has passed
between the original patient visit and clinical adjudication/
reassessment, leading to a less accurate recall of specific
patient encounters by the investigator. In addition, CAC
review of data following completion of all study visits
prevents early identification of potentially incorrect applica-
tion of the multiple DAIs, which can lead to an increase in
protocol deviations and therefore a reduction in the per
protocol population.
A preferable, albeit more labor-intensive approach is
to conduct ongoing data review from the time of screen-
ing through database lock. This approach requires that
patient data be made available to adjudicators soon after
each patient visit, and therefore full-time coordination
by data managers. Adjudicators also need to be avail-
able throughout the course of the trial rather than solely
at the end. Giventhe historyoffailedormodestlysuccessful
development programs for lupus and the complexity of the
disease and its assessments, we favor this approach, however.
In particular, we encourage sponsors to include rigorous
review of all patients screened for entry into the trial
prior to randomization. Most of the trials currently recruit-
ing, as well as those having been run in the recent past
[24￿￿, 31￿￿, 48￿￿], have strict entry criteria to ensure the
following:
1. The patient has been correctly diagnosed as having
lupus.
2. The patient has moderate to severe disease characterized
by at least one A or two B BILAG 2004 body system
scores, as well as a SLEDAI-2K score of 6 or greater.
Most trials are now incorporating a minimum MDGA
score to qualify for a study, as well as a prespecified
type of immunosuppressive regimen.
3. The exclusion of subjects with severe neurological dis-
ease, active antiphospholipid antibody syndrome, and
active lupus nephritis requiring cyclophosphamide, as
these patients often require a different approach to ther-
apy. While many investigators feel comfortable assess-
ing the individual parameters in the SLEDAI-2K and
BILAG 2004 in study patients, many do not have de-
tailed experience in BILAG body system grading, espe-
cially the renal body system. Thus, it is important for
external experts to verify the BILAG 2004 body system
grades for study entry.
4. Another potential issue at screening and baseline visits
that can greatly increase the placebo response rate using
the SRI is the recording of inappropriate SLEDAI 2K
eight-point items as “present.” All of these items, except
for vasculitis, are neurologic features of SLE, most of
which are exclusion criteria. In a post-hoc analysis of
the EMBLEM study, Petri et al. [37￿￿] compared the
SRI with the BICLA using the same dataset and found a
much higher placebo response rate using SRI compared
with BICLA. In this analysis, 61 of 227 (27 %) differed
in assignment of clinical response by SRI or BICLA,
and the majority of these differences (47 SRI, but not
BILAG responders) were explained by a disappearance
of an eight-point item that was recorded at baseline:
lupus headache (n015) or vasculitis (n07). The
intended definition of lupus headache as applied in the
original SLEDAI was that it was a manifestation of
Curr Rheumatol Rep (2012) 14:324–333 327Table 1 Suggested correlation of SLEDAI-2000 and BILAG 2004 clinical parameters for SLE clinical trials
a
SLEDAI-2000 term
b BILAG 2004 parameter
c Comment
Seizure 30. Seizure disorders
31. Status epilepticus
Psychosis 24. Psychosis
(3) Organic brain syndrome 23. Acute confusional state
(4) Visual disturbance
(limited to retinal changes of SLE)
69, 70. Posterior uveitis/retinal
vasculitis—mild and severe
SLEDAI-2000 definition includes only
retinal lesions; original SLEDAI and SELENA-
SLEDAI included all areas of the eye 74. Retinal/choroidal vaso-occlusive disease
75. Isolated cotton-wool spots/cytoid bodies
76. Optic neuritis
77. Anterior ischemic optic neuropathy
(5) Cranial nerve disorder 27. Cranial neuropathy
(6) Lupus headache 37. Lupus headache—severe unremitting Intended to be associated with active
cerebral inflammation 38. Headache from IC hypertension
(7) CVA 32. Cerebrovascular disease
(8) Vasculitis 13. Major cutaneous vasculitis/thrombosis Confirm splinter hemorrhages are
due to serious vasculitis 18. Splinter hemorrhages
20. Cerebral vasculitis
51. Pulmonary hemorrhage/vasculitis
55. Coronary vasculitis
58. Lupus enteritis or colitis if vasculitis
confirmed or other condition in which
vasculitis is documented by imaging or biopsy
(9) Arthritis 41. Arthritis (severe) Note that SLEDAI-2000 requires
≥2 joints involved, while original
SLEDAI and SELENA-SLEDAI
required >2 joints (at least 3)
42. Arthritis (moderate) if
at least 2 joints involved
(10) Myositis 39. Myositis—severe
40. Myositis—mild
(11) Urinary casts 88. Active urinary sediment and
supporting laboratory value
Rarely detected in central laboratory
urine specimens due to transport
requirement; fresh urine sample
in clinic required to detect
(12) Hematuria 88. Active urinary sediment
and supporting laboratory value
(13) Proteinuria >0.5 g/24 h,
new or recent onset
81. Urine dipstick protein ≥3
83. UPCR ≥50 mg/mmol
85. Nephrotic syndrome
(14) Pyuria >5 WBC/hpf,
excluding infection
88. Active urinary sediment
and supporting laboratory value
(15) (New) rash 5. Skin eruption—severe
6. Skin eruption—mild
7. Angioedema—severe
8. Angioedema—mild
17. Periungual erythema/chilblains
(16) Alopecia 15. Alopecia—severe
16. Alopecia—mild
(17) Mucosal ulcers 9. Mucosal ulceration—severe
10. Mucosal ulceration—mild
(18) Pleurisy 48. Pleurisy/pericarditis
50. Pleural effusion with dyspnea
(19) Pericarditis 49. Cardiac tamponade
48. Pleurisy/pericarditis
(20) Low complement Not applicable to BILAG-2004 Not applicable to BILAG-2004
(21) Increased DNA binding Central laboratory value Not applicable to BILAG-2004
(22) Fever 1. Pyrexia, any 1–4 Note difference in glossary definitions
(23) Thrombocytopenia Central laboratory value
(24) Leukopenia Central laboratory value
aThis is a guidance only. Depending on the clinical presentation, other BILAG-2004 terms may match with SLEDAI-2004 terms
bSee Gladman et al. [16]
cSee [20–22]
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shown that headache alone refractory to narcotics is no
more common in the SLE population than in the popu-
lation without lupus [49–52]. The wider availability of
narcotics may falsely elevate the attribution of headache
to SLE. Because the SLEDAI and BILAG are the key
drivers of the SRI and the BICLA responses, it is critical
to make certain that the clinical parameters contained in
both that share similar, if not exactly the same, defini-
tions are scored consistently across both DAIs at every
patient visit. Table 1 shows examples of suggested data
correlations for the DAIs used to measure SLE. Table 2
shows differences in the clinical and laboratory defini-
tions between the BILAG 2004 and SLEDAI-2K glos-
saries. Note that the threshold for common laboratory
abnormalities seen in SLE patients, such as leukopenia
and thrombocytopenia, are different for SLEDAI-2K
and BILAG 2004.
5. Another challenge in using the BILAG 2004 as a key
end point is to ensure that site personnel assign the
features of not present, improving, same, worse, and
new in a logical fashion across different visits. There
are very few clinical scenarios that would result in a
change from “new,”“ worse,” or “same” to “not present”
in the 28-day period specified by the correct use of the
BILAG 2004. Most parameters should go through an
“improving” step before being scored “not present.”
Why is this important? The BILAG 2004 Scoring Index
is based on the intent-to-treat concept [21, 22]. Heavily
weighted clinical parameters will produce an A or B
score when “new,”“ worse,” or “same” are marked, but
reduction to “improving” reduces the body system
grade of an A parameter to B, and a B parameter to C.
In many ongoing lupus phase 2 and phase 3 trials,
swollen/tender joint counts and the Cutaneous LE Ac-
tivity and Severity Index (CLASI) [53] are being used
as exploratory outcome measures, but these tools can
also provide additional data that can be utilized to verify
that the SLEDAI-2K and BILAG are capturing joint and
mucocutaneous parameters correctly. The joint count is
the same 28 tender, swollen joint count used to capture
active joints in rheumatoid arthritis assessments [54,
55], and the CLASI is an index that more precisely
measures lupus skin involvement by applying weighted
scores of activity (rashes, scale, hypertrophy) and dam-
age (dyspigmentation) to segments of the body [53].
The CLASI is more heavily weighted toward areas of
the body that are frequently involved in SLE, such as
the face and scalp, while the Rule of Nines Burn Index
[56], which is used in the BILAG 2004 to assess rash
involvement, can greatly underestimate the degree of
SLE skin involvement. Although both the joint count
and CLASI give a perspective of these parameters only
on the day of the visit, while SLEDAI and BILAG
assess the previous 28 to 30 days, the CLASI and joint
count may be particularly useful in identifying positive
findings that are overlooked on the SLEDAI and
BILAG. For example, if scalp erythema is scored as
present and red on the CLASI, and the patient is noted
to have alopecia, a central adjudicator may query a site
to make certain that the term for “alopecia, severe”
should be considered in addition to “alopecia, mild,”
as erythema would indicate the possible characterization
of inflammation associated with the alopecia.
Table 2 Differences in
SLEDAI-2000 and
BILAG-2004 glossary
definitions
Parameter BILAG-2004 [2–22] SLEDAI-2K [16]
Ophthalmologic Pathology in all areas of the eye Pathology limited to retinal
abnormalities
Arthritis Minimum score requires 1 joint Minimum score requires 2 joints
Fever >37.5°C, 99.5°F >38°C, 100.4°F
Proteinuria Renal score B >0.5 g/24 h00.5 mg/mg0500 mg/g
≥50 mg/mmol00.44 mg/mg0440 mg/g
Pleuritis Requires objective evidence
such as rub or
supportive imaging
Pericarditis Requires objective evidence
such as rub or
supportive imaging
Leukopenia Hematology score C <3,000/mL abnormal
≤3,900/mL considered abnormal
Thrombocytopenia Score if ≤149,000 Score if <100,000
Anti-DNA and
complement
Not included Abnormalities included
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Systemic Lupus Erythematosus Trials
Although central review and adjudication of DAIs for con-
sistency is desirable, and perhaps even essential to assure
high-quality, interpretable data in this heterogeneous patient
population, the execution of this process can be time con-
suming and costly for sponsors. The ideal components of
this venture are included in Fig. 1.
Investigator, Site Personnel, and Monitor Training
and Certification
A uniform, concise, but detailed training program including
SLEDAI, BILAG, correct use of MDGA, CLASI, and joint
count consisting of lectures at Investigator Meetings,
WebEx, and/or video training and certification testing (cur-
rently provided by the Lupus Foundation of America and
others) that can be accessed through Web-based portals is
Fig. 1 Operational aspects of central adjudication for global systemic lupus erythematosus. CRF, case report form
330 Curr Rheumatol Rep (2012) 14:324–333essential. The training and testing should be tailored to the
specific study.
Data Collection and Management
For large, global trials, Internet-based electronic data cap-
ture, case report forms, and source document templates
should be designed with input from the adjudication team
to facilitate collection of the correct data for the DAIs. The
addition of preprogrammed edit checks minimizes manual
queries by adjudicators and streamlines data review. An
experienced data management team should be trained to
streamline communication between adjudicators, sponsors,
CRAs, and site personnel.
Adjudicator Review of Screening Data Prior
to Randomization
Screeningsourcedocuments,subject narrative,andlaboratory
review should be done in a timely fashion to confirm that a
subject has moderate to severe SLE by DAI entry criteria.
On-Study Visits
On site source document verification by monitors should
occur and all outstanding queries addressed before the ad-
judication team reviews the visits.
Pre-database Lock Check for Discrepant Data
Trained data managers should review serial BILAG, SLE-
DAI, and MDGA scores across all visits for each patient to
identify unusual data patterns and have outliers reviewed by
adjudicators.
Confirmation of Response
Responder status should be confirmed by the CAC.
Conclusions
The development of reproducible composite primary end
points such as ACR20, 50, and 70 and DAS28-CRP and
others for the measurement of changes in rheumatoid arthri-
tis activity leads to more interpretable trial end points and a
revolution in the development of drugs for treatment of this
disease compared with 20 years ago [54, 56]. By studying
the differential responsiveness of patients with different
phenotypes and genotypes to the new rheumatoid arthritis
therapies that target specific immunologic pathways, it will
be possible to develop a better understanding of the patho-
genesis and genetics of this disease.
SLE may represent several different diseases given the
extremely variable clinical presentation and organ system
involvement. The clinical development approach to SLE is
more challenging than for rheumatoid arthritis; however,
lessons have been learned from rheumatoid arthritis trials
in constructing potentially viable clinical end points that can
be used in large, global, multicenter trials involving more
than 1,500 patients. While attempts are being made to
develop and validate new versions of existing DAIs [57],
the BILAG and SLEDAI are being used today in ongoing
phase 2 and phase 3 trials. Given the potential subjectivity
and complexity of applying these tools to patients with
different SLE manifestations, it is essential to make certain
that they are being applied uniformly and consistently. This
paper has highlighted the importance of CACs for data
review and confirmation of clinical responses in SLE clin-
ical trials. In addition, we have described a process that is
currently being utilized. While certain features such as grad-
ing of BILAG body systems can be automated with com-
puter algorithms, as in the iBLIPs program developed by
Isenberg et al. [19], and in certain other proprietary data-
bases, which include automatic edit checks, it is neverthe-
less important to incorporate a thoughtful medical review to
ensure consistency in the use of these DAIs in global clinical
trials.
Disclosure MCP receives consultancy fees from UCB Pharma, Inc.,
MedImmune, Inc. and RPS, Inc. LK is a current employee of RPS, Inc.
and a former employee of UCB Pharma, Inc.
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